Systemic lupus erythematosus secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Systemic lupus erythematosus}} {{CMG}}; {{AE}} {{RT}} ==Overview== ===Prevention of complications during pregnancy=== While most infants born to mothers who have SLE are...") |
|||
| (10 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Systemic lupus erythematosus}} | {{Systemic lupus erythematosus}} | ||
{{CMG}}; {{AE}} {{RT}} | {{CMG}}; {{AE}} {{MIR}}, {{RT}} | ||
==Overview== | ==Overview== | ||
Secondary prevention strategies following systemic lupus erythematosus include using [[aspirin]], [[ACE inhibitor|ACE inhibitors]], and [[statins]] to reduce [[Atherosclerotic disease|atherosclerotic diseases]], and using [[Cancer screening|cancer screenings]]. | |||
== | ==Secondary Prevention== | ||
Aims of secondary prevention measures for SLE include:<ref name="pmid22593636">{{cite journal |vauthors=Maidhof W, Hilas O |title=Lupus: an overview of the disease and management options |journal=P T |volume=37 |issue=4 |pages=240–9 |date=April 2012 |pmid=22593636 |pmc=3351863 |doi= |url=}}</ref><ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref> | |||
* Preventing [[glucocorticoid]] usage and using the minimum dosage to prevent [[osteonecrosis]] and [[Osteoporosis|osteoprosis]] side effects | |||
* Decreasing [[Atherosclerosis|atherosclerotic]] events in patients | |||
** Low doses of [[aspirin]] | |||
** [[ACE inhibitor|ACE inhibitors]] | |||
** [[Statins]] | |||
* For prevention and/or early diagnosis of [[malignancies]]: | |||
** Regular age-related specific [[cancer screening]] recommended for the general population | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Arthritis]] | |||
[[Category:Dermatology]] | |||
[[Category:Diseases involving the fasciae]] | |||
[[Category:Rheumatology]] | |||
[[Category:Nephrology]] | |||
[[Category:Autoimmune diseases]] | |||
[[Category:Disease]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 13:41, 6 June 2018
|
Systemic lupus erythematosus Microchapters |
|
Differentiating Systemic lupus erythematosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Systemic lupus erythematosus secondary prevention On the Web |
|
American Roentgen Ray Society Images of Systemic lupus erythematosus secondary prevention |
|
Systemic lupus erythematosus secondary prevention in the news |
|
Directions to Hospitals Treating Systemic lupus erythematosus |
|
Risk calculators and risk factors for Systemic lupus erythematosus secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2], Raviteja Guddeti, M.B.B.S. [3]
Overview
Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.
Secondary Prevention
Aims of secondary prevention measures for SLE include:[1][2]
- Preventing glucocorticoid usage and using the minimum dosage to prevent osteonecrosis and osteoprosis side effects
- Decreasing atherosclerotic events in patients
- Low doses of aspirin
- ACE inhibitors
- Statins
- For prevention and/or early diagnosis of malignancies:
- Regular age-related specific cancer screening recommended for the general population
References
- ↑ Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
- ↑ Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.